Roles of chemokine CXCL12 and its receptors in ischemic stroke

Current Drug Targets

Volumn 13, Issue 2, 2012, Pages 166-172

  Wang, Yongting ^a   Huang, Jun ^a   Li, Yaning ^a   Yang, Guo Yuan ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angiogenesis; CXCL12; CXCR4; CXCR7; Inflammation; Stroke

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; FLUINDOSTATIN; PLERIXAFOR;

ANGIOGENESIS; ASTROCYTE; BRAIN; BRAIN ISCHEMIA; CELL TYPE; HUMAN; INFLAMMATION; MICROGLIA; NERVE CELL; NONHUMAN; REVIEW; STEM CELL;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CHEMOKINE CXCL12; HUMANS; RECEPTORS, CXCR4; STROKE;

EID: 84863167179     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012799201603     Document Type: Review

References (101)

1. Liu S, Levine SR. The Continued Promise of Neuroprotection for Acute Stroke Treatment. J Exp Stroke Transl Med 2008; 1: 1-8.
2. Nanetti L, Taffi R, Vignini A, et al. Reactive oxygen species plasmatic levels in ischemic stroke. Mol Cell Biochem 2007; 303: 19-25.
3. Pawate S, Shen Q, Fan F, Bhat NR. Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. J Neurosci Res 2004; 77: 540-551.
4. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007; 184: 53-68.
5. Emsley HC, Tyrrell PJ. Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab 2002; 22: 1399-1419.
6. Odemis V, Boosmann K, Heinen A, Kury P, Engele J. CXCR7 is an active component of SDF-1 signalling in astrocytes and Schwann cells. Journal of cell science 2010; 123: 1081-1088.
7. Hill WD, Hess DC, Martin-Studdard A, et al. SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury. J Neuropathol Exp Neurol 2004; 63: 84-96.
8. Thored P, Arvidsson A, Cacci E, et al. Persistent production of neurons from adult brain stem cells during recovery after stroke. Stem Cells 2006; 24: 739-747.
9. Ohab JJ, Fleming S, Blesch A, Carmichael ST. A neurovascular niche for neurogenesis after stroke. J Neurosci 2006; 26: 13007-13016.
10. Del Zoppo GJ, Milner R, Mabuchi T, et al. Vascular matrix adhesion and the blood-brain barrier. Biochem Soc Trans 2006; 34: 1261-1266.
11. Robin AM, Zhang ZG, Wang L, et al. Stromal cell-derived factor 1alpha mediates neural progenitor cell motility after focal cerebral ischemia. J Cereb Blood Flow Metab 2006; 26: 125-134.
12. Janowski M. Functional diversity of SDF-1 splicing variants. Cell Adh Migr 2009; 3: 243-249.
13. Murphy JW, Yuan H, Kong Y, Xiong Y, Lolis EJ. Heterologous quaternary structure of CXCL12 and its relationship to the CC chemokine family. Proteins 2010; 78: 1331-1337.
14. Tashiro K, Tada H, Heilker R, et al. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 1993; 261: 600-603.
15. Rostene W, Buckingham JC. Chemokines as modulators of neuroendocrine functions. J Mol Endocrinol 2007; 38: 351-353.
16. Davis DA, Singer KE, De La Luz Sierra M, et al. Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation. Blood 2005; 105: 4561-4568.
17. Gleichmann M, Gillen C, Czardybon M, et al. Cloning and characterization of SDF-1gamma, a novel SDF-1 chemokine transcript with developmentally regulated expression in the nervous system. Eur J Neurosci 2000; 12: 1857-1866.
18. Rueda P, Balabanian K, Lagane B, et al. The CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins. PLoS One 2008; 3: e2543.
19. Crump MP, Gong JH, Loetscher P, et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. Embo J 1997; 16: 6996-7007.
20. Dealwis C, Fernandez EJ, Thompson DA, et al. Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1alpha, a potent ligand for the HIV-1 fusin coreceptor. Proc Natl Acad Sci U S A 1998; 95: 6941-6946.
21. Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998; 4: 72-77.
22. Wong ML, Xin WW, Duman RS. Rat LCR1: cloning and cellular distribution of a putative chemokine receptor in brain. Mol Psychiatry 1996; 1: 133-140.
23. Westmoreland SV, Rottman JB, Williams KC, Lackner AA, Sasseville VG. Chemokine receptor expression on resident and inflammatory cells in the brain of macaques with simian immunodeficiency virus encephalitis. Am J Pathol 1998; 152: 659-665.
24. Tanabe S, Heesen M, Yoshizawa I, et al. Functional expression of the CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes. J Immunol 1997; 159: 905-911.
25. Jazin EE, Soderstrom S, Ebendal T, Larhammar D. Embryonic expression of the mRNA for the rat homologue of the fusin/CXCR-4 HIV-1 co-receptor. J Neuroimmunol 1997; 79: 148-154.
26. Bajetto A, Bonavia R, Barbero S, et al. Glial and neuronal cells express functional chemokine receptor CXCR4 and its natural ligand stromal cell-derived factor 1. J Neurochem 1999; 73: 2348-2357.
27. Zhou N, Luo Z, Luo J, et al. Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies. The Journal of biological chemistry 2001; 276: 42826-42833.
28. Libert F, Parmentier M, Lefort A, Dumont JE, Vassart G. Complete nucleotide sequence of a putative G protein coupled receptor: RDC1. Nucleic acids research 1990; 18: 1917.
29. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-864.
30. Stumm RK, Rummel J, Junker V, et al. A dual role for the SDF- 1/CXCR4 chemokine receptor system in adult brain: isoformselective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J Neurosci 2002; 22: 5865-5878.
31. Nagase H, Miyamasu M, Yamaguchi M, et al. Cytokine-mediated regulation of CXCR4 expression in human neutrophils. J Leukoc Biol 2002; 71: 711-717.
32. Kolodziej A, Schulz S, Guyon A, et al. Tonic activation of CXC chemokine receptor 4 in immature granule cells supports neurogenesis in the adult dentate gyrus. J Neurosci 2008; 28: 4488-4500.
33. Salcedo R, Wasserman K, Young HA, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 1999; 154: 1125-1135.
34. Sierro F, Biben C, Martinez-Munoz L, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A 2007; 104: 14759-14764.
35. Schonemeier B, Schulz S, Hoellt V, Stumm R. Enhanced expression of the CXCl12/SDF-1 chemokine receptor CXCR7 after cerebral ischemia in the rat brain. J Neuroimmunol 2008; 198: 39-45.
36. Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF- 1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. The Journal of biological chemistry 2005; 280: 35760-3576.
37. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007; 28: 299-307.
38. Tham TN, Lazarini F, Franceschini IA, et al. Developmental pattern of expression of the alpha chemokine stromal cell-derived factor 1 in the rat central nervous system. Eur J Neurosci 2001; 13: 845-856.
39. Lu M, Grove EA, Miller RJ. Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor. Proc Natl Acad Sci U S A 2002; 99: 7090-7095.
40. Revy P, Busslinger M, Tashiro K, et al. A syndrome involving intrauterine growth retardation, microcephaly, cerebellar hypoplasia, B lymphocyte deficiency, and progressive pancytopenia. Pediatrics 2000; 105: E39.
41. Kodali R, Hajjou M, Berman AB, et al. Chemokines induce matrix metalloproteinase-2 through activation of epidermal growth factor receptor in arterial smooth muscle cells. Cardiovasc Res 2006; 69: 706-715.
42. Chinni SR, Sivalogan S, Dong Z, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 2006; 66: 32-48.
43. Bajetto A, Barbero S, Bonavia R, et al. Stromal cell-derived factor- 1alpha induces astrocyte proliferation through the activation of extracellular signal-regulated kinases 1/2 pathway. J Neurochem 2001; 77: 1226-1236.
44. Majka M, Ratajczak J, Kowalska MA, Ratajczak MZ. Binding of stromal derived factor-1alpha (SDF-1alpha) to CXCR4 chemokine receptor in normal human megakaryoblasts but not in platelets induces phosphorylation of mitogen-activated protein kinase p42/44 (MAPK), ELK-1 transcription factor and serine/threonine kinase AKT. Eur J Haematol 2000; 64: 164-172.
45. Hirsch E, Katanaev VL, Garlanda C, et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000; 287: 1049-1053.
46. Wang JF, Park IW, Groopman JE. Stromal cell-derived factor- 1alpha stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: roles of phosphoinositide-3 kinase and protein kinase C. Blood 2000; 95: 2505-2513.
47. Mahabaleshwar H, Boldajipour B, Raz E. Killing the messenger: The role of CXCR7 in regulating primordial germ cell migration. Cell Adh Migr 2008; 2: 69-70.
48. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009; 113: 6085-6093.
49. Iwakiri S, Mino N, Takahashi T, et al. Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer 2009; 115: 2580-2593.
50. Meijer J, Ogink J, Roos E. Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br J Cancer 2008; 99: 1493-1501.
51. Miao Z, Luker KE, Summers BC, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumorassociated vasculature. Proc Natl Acad Sci U S A 2007; 104: 15735-15740.
52. Wang J, Shiozawa Y, Wang J, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. The Journal of biological chemistry 2008; 283: 4283-4294.
53. Zabel BA, Wang Y, Lewen S, et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol 2009; 183: 3204-3211.
54. Zheng K, Li HY, Su XL, et al. Chemokine receptor CXCR7 regulates the invasion,angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2010; 29: 31.
55. Tarnowski M, Grymula K, Reca R, et al. Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. Mol Cancer Res 2010; 8: 1-14.
56. Kalatskaya I, Berchiche YA, Gravel S, et al. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 2009; 75: 1240-1247.
57. Rajagopal S, Kim J, Ahn S, et al. Beta-arrestin- but not G proteinmediated signaling by the decoy receptor CXCR7. Proc Natl Acad Sci U S A 2010; 107: 628-632.
58. Grymula K, Tarnowski M, Wysoczynski M, et al. Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int J Cancer 2010; 127: 2554-2568.
59. Yoshida D, Nomura R, Teramoto A. Signaling Pathway Mediated by CXCR7, an Alternative Chemokine Receptor for Stromal-Cell Derived Factor-1alpha, in AtT20 mouse ACTH-secreting pituitary adenoma cells. J Neuroendocrinol 2009; 21: 481-488.
60. Mazzinghi B, Ronconi E, Lazzeri E, et al. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. The Journal of experimental medicine 2008; 205: 479-490.
61. Samson Y, Lapergue B, Hosseini H. [Inflammation and ischaemic stroke: current status and future perspectives]. Rev Neurol (Paris) 2005; 161: 1177-1182.
62. Chamorro A, Amaro S, Vargas M, et al. Interleukin 10, monocytes and increased risk of early infection in ischaemic stroke. J Neurol Neurosurg Psychiatry 2006; 77: 1279-1281.
63. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999; 19: 819-834.
64. Becker KJ. Inflammation and acute stroke. Curr Opin Neurol 1998; 11: 45-49.
65. Davies CA, Loddick SA, Stroemer RP, Hunt J, Rothwell NJ. An integrated analysis of the progression of cell responses induced by permanent focal middle cerebral artery occlusion in the rat. Exp Neurol 1998; 154: 199-212.
66. Hallenbeck JM. Significance of the inflammatory response in brain ischemia. Acta Neurochir Suppl 1996; 66: 27-31.
67. Zheng Z, Yenari MA. Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurol Res 2004; 26: 884-892.
68. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004; 16: 1-13.
69. Prat A, Biernacki K, Wosik K, Antel JP. Glial cell influence on the human blood-brain barrier. Glia 2001; 36: 145-155.
70. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003; 3: 569-581.
71. Bajetto A, Bonavia R, Barbero S, Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem 2002; 82: 1311-1329.
72. Negrete-Garcia MC, Velazquez JR, Popoca-Coyotl A, et al. CXCL12/SDF-1 is associated with leukocyte recruitment in asthma. Chest 2010;
73. Moll NM, Cossoy MB, Fisher E, et al. Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol 2009; 66: 44-53.
74. Petty JM, Sueblinvong V, Lenox CC, et al. Pulmonary stromalderived factor-1 expression and effect on neutrophil recruitment during acute lung injury. J Immunol 2007; 178: 8148-8157.
75. Felszeghy K, Banisadr G, Rostene W, Nyakas C, Haour F. Dexamethasone downregulates chemokine receptor CXCR4 and exerts neuroprotection against hypoxia/ischemia-induced brain injury in neonatal rats. Neuroimmunomodulation 2004; 11: 404-413.
76. Peng H, Erdmann N, Whitney N, et al. HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1beta. Glia 2006; 54: 619-629.
77. Odemis V, Moepps B, Gierschik P, Engele J. Interleukin-6 and cAMP induce stromal cell-derived factor-1 chemotaxis in astroglia by up-regulating CXCR4 cell surface expression. Implications for brain inflammation. The Journal of biological chemistry 2002; 277: 39801-39808.
78. Yao JS, Zhai W, Young WL, Yang GY. Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. Biochem Biophys Res Commun 2006; 342: 1396-1404.
79. Lu DY, Tang CH, Yeh WL, et al. SDF-1alpha up-regulates interleukin-6 through CXCR4, PI3K/Akt, ERK, and NF-kappab dependent pathway in microglia. European journal of pharmacology 2009; 613: 146-154.
80. McCandless EE, Wang Q, Woerner BM, Harper JM, Klein RS. CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J Immunol 2006; 177: 8053-8064.
81. Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke 2007; 38: 748-752.
82. Shao H, Tan Y, Eton D, et al. Statin and stromal cell-derived factor- 1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells 2008; 26: 1376-1384.
83. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-637.
84. Hiasa K, Ishibashi M, Ohtani K, et al. Gene transfer of stromal cellderived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 2004; 109: 2454-2461.
85. Hattori K, Heissig B, Tashiro K, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001; 97: 3354-3360.
86. Shiba Y, Takahashi M, Hata T, et al. Bone marrow CXCR4 induction by cultivation enhances therapeutic angiogenesis. Cardiovasc Res 2009; 81: 169-177.
87. Zemani F, Silvestre JS, Fauvel-Lafeve F, et al. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol 2008; 28: 644-650.
88. Ho TK, Tsui J, Xu S, et al. Angiogenic effects of stromal cellderived factor-1 (SDF-1/CXCL12) variants in vitro and the in vivo expressions of CXCL12 variants and CXCR4 in human critical leg ischemia. J Vasc Surg 2010; 51: 689-699.
89. Hartmann TN, Grabovsky V, Pasvolsky R, et al. A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokinetriggered motility of human T lymphocytes and CD34+ cells. J Leukoc Biol 2008; 84: 1130-1140.
90. Gage FH, Ray J, Fisher LJ. Isolation, characterization, and use of stem cells from the CNS. Annu Rev Neurosci 1995; 18: 159-192.
91. Brustle O, Spiro AC, Karram K, et al. In vitro-generated neural precursors participate in mammalian brain development. Proc Natl Acad Sci U S A 1997; 94: 14809-14814.
92. Klein RS, Rubin JB. Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticity. Trends Immunol 2004; 25: 306-314.
93. Tiveron MC, Rossel M, Moepps B, et al. Molecular interaction between projection neuron precursors and invading interneurons via stromal-derived factor 1 (CXCL12)/CXCR4 signaling in the cortical subventricular zone/intermediate zone. J Neurosci 2006; 26: 13273-13278.
94. Imitola J, Raddassi K, Park KI, et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A 2004; 101: 18117-18122.
95. Peng H, Huang Y, Rose J, et al. Stromal cell-derived factor 1- mediated CXCR4 signaling in rat and human cortical neural progenitor cells. J Neurosci Res 2004; 76: 35-50.
96. Wu Y, Peng H, Cui M, et al. CXCL12 increases human neural progenitor cell proliferation through Akt-1/FOXO3a signaling pathway. J Neurochem 2009; 109: 1157-1167.
97. Matthys P, Hatse S, Vermeire K, et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFNgamma receptor-deficient mice. J Immunol 2001; 167: 4686-4692.
98. Lukacs NW, Berlin A, Schols D, Skerlj RT, Bridger GJ. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol 2002; 160: 1353-1360.
99. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009; 77: 1655-1664.
100. Shepherd RM, Capoccia BJ, Devine SM, et al. Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. Blood 2006; 108: 3662-3667.
101. Zhao C, Wang J, Zhao S, Nie Y. Constraint-induced movement therapy enhanced neurogenesis and behavioral recovery after stroke in adult rats. Tohoku J Exp Med 2009; 218: 301-308.